Refana

News

  • Home
  • Programs
    • AI in Medicine
    • Vaccines
    • Early Cancer Detection
  • Corporate
  • Team
  • About
  • Blog
    • News
    • COVID Industry Updates

11/27/2021

Could WIV Vaccines hold the key to beating the new super strain

0 Comments

Read Now
 
Picture
By ETHAN ENNALS FOR THE MAIL ON SUNDAY

​
Experts told The Mail on Sunday that there is one jab ready to go that might already be highly effective against this version of the virus: the one developed by French firm Valneva and ordered by the UK Government – but then cancelled.
​

It could have an advantage over current jabs because the way it’s been made differs.

It contains what is known as a fully inactivated virus – a whole Covid virus that has been neutralised. 
Though it can’t cause illness, the immune system reacts by recognising the threat and creating antibodies and other fighter cells, enabling the body to fight off the real virus if it becomes infected.

​Other shots such as Pfizer and AstraZeneca use genetic fragments from one part of the Covid virus, called the spike protein – the section that allows it to bind with healthy cells.

It is this part that’s prone to mutations: the 32 mutations seen in the Botswana variant are all found on the spike protein, which increases the chances that the antibodies developed in response to the above vaccines may not ‘recognise’ it, allowing the virus to slip past.

Since the Valneva jab has more parts of the virus for the immune system to learn from, experts believe it could be more ‘variant-proof’ than the others.

Professor Adam Finn, paediatrician and member of the Joint Committee on Vaccination and Immunisation, the Government’s advisory group, says there is a ‘strong theoretical argument’ that the Valneva jab could provide protection against the Botswana variant. 

‘This is potentially a more resilient vaccine,’
he said. 

‘Obviously we’d need to look at how it reacts to this particular variant but I think there’s a strong argument for doing that right now.’
​
Trial results published last month found two doses of Valneva were 95 per cent effective at preventing infection. The trial of 4,000 participants also reported no cases of severe illness.
​
Read the full article

Back to Blog

Share

0 Comments
Details

    Categories

    All
    Artificial Intelligence
    Covid 19
    Early Cancer Detection
    Press Release

    Archives

    May 2022
    April 2022
    March 2022
    January 2022
    December 2021
    November 2021
    October 2021
    September 2021
    June 2021
    May 2021
    April 2021
    March 2021
    February 2021
    January 2021
    December 2020
    November 2020
    October 2020
    July 2020
    June 2020

    RSS Feed

​Practical Solutions for complex and ​urgent global medical problems

HOME     |     PROGRAMS    |    TEAM     |     ABOUT     |     NEWS
Privacy Policy | Cookie Policy
© 2022 Refana Inc
  • Home
  • Programs
    • AI in Medicine
    • Vaccines
    • Early Cancer Detection
  • Corporate
  • Team
  • About
  • Blog
    • News
    • COVID Industry Updates